Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia | Latest News RSS feed

Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia - Latest News


Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreate... read more

Ibrutinib-based regimen superior to standard chemoimmunotherapy in chronic lymphocytic leukemia

SAN DIEGO — The combination of ibrutinib and rituximab conferred superior PFS and OS compared with standard chemoimmunotherapy among previously untreated younger patients with chronic lymphocytic leuk... read more

Phase 3 trial finds ibrutinib in combo with rituximab superior to standard treatment for some patients with CLL

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreate... read more

Looking for another news?


Ibrutinib Established as Standard for Older CLL Patients

Ibrutinib (Imbruvica) as monotherapy and combined with rituximab (Rituxan) significantly improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) as frontline therapy fo... read more


Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL

According to the results of Alliance A041202, an international multicenter phase 3 trial, ibrutinib produces superior progression-free survival (PFS) compared with standard ... plus rituximab in untre... read more

Ibrutinib Alone for Older Patients With Untreated CLL

SAN DIEGO — In older patients >65 years with untreated chronic lymphocytic leukemia (CLL ... residual disease with the ibrutinib-containing regimens compared with the bendamustine plus rituximab sugge... read more

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

"For both multiple myeloma and chronic lymphocytic leukemia ... the combination of ibrutinib plus rituximab as the most effective first-line treatment for CLL patients age 70 and younger." read more

Ibrutinib Significantly Improves PFS in Older Untreated Patients With CLL

was significantly improved with both ibrutinib (Imbruvica) as monotherapy and in combination with rituximab (Rituxan) when compared to bendamustine plus rituximab (BR) as a treatment for older patient... read more

New drug combination for treating Chronic Leukemia

Combination of ibrutinib plus rituximab was found superior to the old treatment for patients aged ... suffering from chronic lymphocytic leukemia could benefit more by using new combination chemothera... read more

Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukemia

Results from an multi-institutional, phase 3 clinical trial show that older patients with chronic ... plus rituximab, a more effective regimen. "Our results establish that ibrutinib should be a ... read more

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia ... plus obinutuzumab 3 or bendamustine plus rituximab 4 has s... read more

Ibrutinib and Rituximab for Untreated CLL: 'Practice Changing'

beat the current gold standard of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with untreated chronic lymphocytic leukemia (CLL) in a large trial funded by the National C... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us